Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering, which may have artificially deflated the stock price prior to a merger announcement with AbbVie Inc. [1][4] Group 1: Allegations and Impact - The lawsuit claims that Cerevel's October 16, 2023 secondary stock offering documents omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [4] - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie announced the acquisition at $45 per share [4] - Cerevel's January 18, 2024 Proxy statement is accused of misleading investors regarding the nature and timing of AbbVie's interest in the company [4] Group 2: Class Action Details - The class period for the lawsuit includes all persons or entities that sold or disposed of Cerevel's common stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [3] - Shareholders are encouraged to register for the class action by June 3, 2025, to participate in potential recovery without any cost or obligation [5] - The Gross Law Firm aims to protect investors' rights and ensure responsible business practices by seeking recovery for losses incurred due to misleading statements or omissions [6]

Core Viewpoint - The Gross Law Firm is notifying shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit due to alleged misleading statements and operational inefficiencies that negatively impacted the company's financial performance during the specified class period [1][3]. Group 1: Allegations - The complaint alleges that West Pharmaceutical Services issued materially false and misleading statements regarding customer demand visibility and attributed operational challenges to temporary COVID-related product destocking, while in reality, the company faced significant ongoing destocking in its high-margin HVP portfolio [3]. - It is claimed that the SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. - As a result of these factors, the positive statements made by the defendants about the company's business and prospects were materially false or misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 16, 2023, to February 12, 2025, with a deadline for shareholders to register for the class action set for July 7, 2025 [3][4]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case, and there is no cost or obligation to participate [4]. - The Gross Law Firm emphasizes its commitment to protecting investors' rights and ensuring companies adhere to responsible business practices [5].

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Canopy Growth Corporation (NASDAQ: CGC). Shareholders who purchased shares of CGC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/canopy-growth-corporation-loss-submission-form-2/?id=147741&from=3 CLASS PE ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Fluence Energy, Inc. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's financial performance and relationships with key partners [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from October 28, 2021, to February 10, 2025 [3]. - Allegations include that Fluence's relationships with Siemens AG and The AES Corporation were expected to decline, and that Siemens Energy accused Fluence of engineering failures and fraud [3]. - It is claimed that Fluence's reported margins and revenue growth were inflated as Siemens and AES were moving to divest, leading to a lack of reasonable basis for positive statements regarding Fluence's battery energy storage business and financial prospects [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of May 12, 2025, to potentially be appointed as lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ibotta, Inc. (NYSE: IBTA). Shareholders who purchased shares of IBTA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/ibotta-loss-submission-form/?id=147735&from=3 CLASS PERIOD: This lawsuit is on behalf of ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information affecting the company's stock value [1]. Group 1: Allegations and Impact - The complaint alleges that during the class period from May 8, 2023, to May 7, 2024, Treace Medical faced competition that negatively impacted the demand for its primary product, the 3D bunion correction system known as "Lapiplasty" [1]. - As a result of the competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [1]. - The defendants are accused of making materially misleading statements about the company's business operations and future prospects, lacking a reasonable basis [1]. Group 2: Class Action Details - Shareholders who purchased TMCI shares during the specified class period are encouraged to register for the class action, with a deadline set for June 10, 2025 [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. - Participation in the case does not incur any cost or obligation for the shareholders [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that led to artificial inflation of the company's stock [3].

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the material weaknesses in SoundHound's internal controls over financial reporting impaired the Company's ability to effectively account for corporate acquisitions; (ii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial repor ...

CLASS PERIOD: This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Ibotta securities pursuant and/or traceable to documents issued in connection with Ibotta's April 18, 2024 initial public offering. ALLEGATIONS: According to the filed complaint, defendants made false statements and/or concealed that they did not properly warn investors of the risks concerning Ibotta's contract with The Kroger Co. ("Kroger"). Kroger's contract was at-will, and Ibotta failed to ...

Core Viewpoint - The Gross Law Firm has initiated a class action lawsuit on behalf of shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV) due to alleged misleading statements and omissions related to a secondary stock offering and subsequent merger with AbbVie Inc. [1][2] Group 1: Allegations and Impact - Cerevel's October 16, 2023 secondary stock offering documents allegedly omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which artificially deflated Cerevel's stock price until the merger announcement [2] - Bain Capital, Cerevel's controlling shareholder, reportedly acquired shares at the depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall exceeding $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [2] - Cerevel's January 18, 2024 Proxy statement is claimed to have misled investors regarding the nature and timing of AbbVie's interest in the company [2] Group 2: Class Action Details - The class period for the lawsuit includes shareholders who sold or disposed of Cerevel stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [1][2] - The deadline for shareholders to register for the class action and seek lead plaintiff status is June 3, 2025, with no cost or obligation to participate [3]

Core Viewpoint - Fluence Energy, Inc. is facing allegations of issuing materially false and misleading statements regarding its business operations and financial performance during the class period from October 28, 2021, to February 10, 2025 [1] Allegations - The complaint claims that Fluence's relationship with its founders and major revenue sources, Siemens AG and The AES Corporation, was expected to decline [1] - Siemens Energy, the U.S. affiliate of Siemens AG, accused Fluence of engineering failures and fraud [1] - Fluence's reported margins and revenue growth were allegedly inflated as Siemens and AES were moving towards divestment [1] - Due to the aforementioned issues, the defendants reportedly lacked a reasonable basis for their positive statements regarding Fluence's battery energy storage business and its financial results, growth, and prospects [1] Class Action Details - Shareholders who purchased FLNC shares during the specified class period are encouraged to register for the class action by May 12, 2025 [2] - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates throughout the case [2] - There is no cost or obligation for shareholders to participate in the case [2]